Stock Traders Buy Large Volume of Climb Bio Call Options (NASDAQ:CLYM)

Key Points

• Call-option activity surged: Investors bought 3,024 Climb Bio call options, a 740% increase over the average volume of 360 contracts.
• Climb Bio is advancing a Phase 2 trial in China, while analysts remain broadly bullish; the stock has a consensus “Buy” rating and an average price target of $23.08.
• Shares fell 6.7% to $16.65 and remain unprofitable, with analysts forecasting a full-year loss of $0.84 per share despite the stock trading near its 12-month high.

Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) saw unusually large options trading activity on Wednesday. Stock investors purchased 3,024 call options on the stock. This represents an increase of 740% compared to the average volume of 360 call options.

Trending Headlines about Climb Bio

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Climb Bio is advancing a Phase 2 trial in China, a potentially important step for its clinical program and future commercial opportunities. The development provides a fundamental catalyst, although investors may be waiting for additional trial data. Climb Bio Advances Phase 2 Trial in China
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $24 price target, above the stock’s recent trading level. The firm also improved its loss estimates, forecasting a 2026 loss of $0.76 per share versus $0.93 previously, with smaller projected quarterly losses of $0.20 in Q3 and $0.19 in Q4.
• Neutral Sentiment: The valuation may already reflect much of the optimism surrounding the China trial and the company’s broader pipeline. Climb Bio trades near its 12-month high, while it remains unprofitable; the consensus forecast calls for a $0.84-per-share loss this fiscal year.
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from the prior report. The resulting zero-day short-interest ratio suggests short covering is not a factor influencing the stock’s current move, although the data may be incomplete or anomalous.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC acquired a new stake in Climb Bio in the first quarter worth about $27,000. Virtu Financial LLC acquired a new position in shares of Climb Bio during the fourth quarter valued at about $43,000. Qube Research & Technologies Ltd purchased a new position in shares of Climb Bio in the 2nd quarter valued at approximately $43,000. Blair William & Co. IL purchased a new position in shares of Climb Bio in the 4th quarter valued at approximately $44,000. Finally, Legal & General Group Plc acquired a new stake in Climb Bio in the 2nd quarter worth approximately $45,000. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

Climb Bio Stock Down 6.7%

Shares of NASDAQ CLYM traded down $1.19 during trading hours on Wednesday, hitting $16.65. 410,463 shares of the stock were exchanged, compared to its average volume of 939,391. The company has a market cap of $956.38 million, a PE ratio of -20.06 and a beta of 0.08. The firm has a fifty day moving average price of $13.59 and a 200-day moving average price of $10.29. Climb Bio has a 12 month low of $1.54 and a 12 month high of $18.33.

Climb Bio (NASDAQ:CLYM - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03. As a group, equities analysts anticipate that Climb Bio will post -0.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Wall Street Zen upgraded shares of Climb Bio from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. BTIG Research increased their price objective on shares of Climb Bio from $19.00 to $20.00 and gave the company a "buy" rating in a research note on Thursday, June 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of Climb Bio in a report on Friday, July 17th. Wedbush restated an "outperform" rating and set a $20.00 target price on shares of Climb Bio in a report on Wednesday, August 19th. Finally, Chardan Capital began coverage on Climb Bio in a research report on Tuesday, May 5th. They set a "buy" rating and a $22.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $23.08.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company's mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio's approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source